U.S. market Closed. Opens in 5 hours 56 minutes

FRLN | Freeline Therapeutics Holdings plc Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue1.74M2.39M1.93M1.55MN/A
Gross Profit-1.74M-2.39M-1.93M-1.55MN/A
Operating Expenses95.29M137.91M87.18M53.05M32.72M
Selling, General & Admin30.66M44.57M26.30M16.60M6.79M
Research & Development66.20M95.43M76.15M47.04M34.19M
Other Operating Expenses-1.57M-2.09M-15.27M-10.60M-390.00K
Operating Income-98.45M-142.38M-102.45M-63.64M-40.98M
Other Expenses / Income9.84M2.33M6.26M9.88M-390.00K
Before Tax Income-88.60M-140.05M-96.19M-53.77M-33.26M
Income Tax Expenses368.00K342.00K129.00K141.00K27.00K
Net Income-88.97M-140.39M-96.32M-53.91M-33.28M
Interest Expenses-10.31MN/AN/AN/A151.00K
Basic Shares Outstanding3.95M2.38M943.52K423.19K423.19K
Diluted Shares Outstanding3.95M2.38M943.52K423.19K423.19K
EBITDA-97.17M-133.14M-85.27M-51.51M-32.13M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-98.92M-140.05M-96.19M-53.77M-33.10M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙